Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Berg, Anne Marie; Dahl, Alv A.; Bruland, Øyvind S.; Bjøro, Trine; Aanensen, Mai Sasaki; Fosså, Sophie D.

doi:10.1038/pcan.2009.8

Cited by 7 publications

(2 citation statements)

References 32 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quality of life is often linked to testosterone levels [14,[31][32][33][34]. However, not all authors confirm that lowered testosterone is devastating for the male quality of life [35][36][37]. In the questionnaire created to survey the special problems secondary to hormonal equilibrium, the differences were confirmed, with worse results in patients treated with pharmacological castration.…”

Section: Discussionmentioning

confidence: 99%

Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

et al. 2011

View full text Add to dashboard Cite

show abstract

“…One suggested explanation found in the literature is that aspirin and other NSAIDs lower PSA levels, but is not itself anti-tumorigenic (Berg et al, 2009; Schroder et al, 2009). If true, this would likely delay diagnosis of the disease, allowing it to progress unnoticed.…”

Section: Decreased Psa Levels In Chronic Aspirin Users Among Prostatementioning

confidence: 99%

Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms

2017

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is a critical health burden, impacting the morbidity and mortality of millions of men around the world. Most of the patients with PCa have their disease at first sensitive to androgen deprivation treatments, but later they develop resistance to therapy and eventually die of metastatic castration-resistant prostate cancer (CRPC). Although the newly developed anti-androgen therapies are effectively alleviating symptoms and prolonging lives of patients, there are still no curable treatments for CRPC. Recently, statistical studies have shown that the chronic use of aspirin might be significantly associated with better outcomes in PCa patients. Through this review, we aim to identify the different proposed molecular mechanisms relating aspirin to the pathobiology of PCa neoplasms, with a major focus on basic research done in this context.Methods: Articles were retrieved via online database searching of PubMed and MEDLINE between 1946 and September 2016. Keywords and combinations related to PCa and aspirin were used to perform the search. Abstracts of the articles were studied by two independent reviewers and then data extraction was performed on the relevant articles that met our review objectives.Results: Aspirin, a non-steroidal anti-inflammatory drug (NSAID), affects the proliferation, apoptosis, resistance and metastasis of PCa cell lines, through both COX-dependent and COX-independent mechanisms. It also lowers levels of the PCa diagnostic marker prostate specific antigen (PSA), suggesting that clinicians need to at least be aware if their patients are using Aspirin chronically.Conclusion: This review strongly warrants further consideration of the signaling cascades activated by aspirin, which may lead to new knowledge that might be applied to improve diagnosis, prognosis and treatment of PCa.

show abstract

Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer

et al. 2015

View full text Add to dashboard Cite

High-dose IMRT, combined with NA-ADT for LAPC, was associated with favorable long-term disease-specific and overall survival outcomes, despite non-provision of A-ADT under the early S-ADT provision policy. This approach may represent a viable alternative to uniform provision of long-term A-ADT, because two-thirds of the patients maintained ADT-free status over an 8-year period after IMRT. Prospective trials will be required.

show abstract

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

Cited by 7 publications

References 32 publications

Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms

Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer

Contact Info

Product

Resources

About